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Abstract
Benign tremulous parkinsonism (BTP) is characterized by a prominent tremor that occurs both at rest and with
action in conjunction with other mild features of parkinsonism. The progression of symptoms is typically slow and
there is often a positive family history. Although BTP is included within the phenotypic spectrum of Parkinsonism its
exact relationship with idiopathic Parkinson’s disease remains unclear. Treatment of BTP is challenging especially
considering the poor response to levodopa, therefore surgical therapies such as deep brain stimulation surgery are
sought for treatment of these tremors. In this review, we will summarize the clinical features, diagnosis,
neuropathology and treatment for BTP.
Background
Tremor is a common symptom seen in movement disor-
ders clinical practice [1, 19]. The most common cause of
tremors is essential tremor and the other important dif-
ferential is idiopathic Parkinson’s disease (PD)[2–5]. The
basic difference between the arm tremors seen in these
two conditions is that essential tremor is characterized
by postural and action tremor whereas PD tremor is
mostly a resting tremor [11]. Benign tremulous parkin-
sonism was first characterized extensively in cohort of
16 patients followed at Mayo Clinic who shared similar
phenotype and exhibited a unique clinical course. These
patients had a pronounced asymmetric resting tremor in
conjunction with mild to moderate postural and action
tremor and mild parkinsonian signs. The tremors did
not respond to alcohol. Although this constellation of
features was tempting to be categorized as PD, the clini-
cians at Mayo Clinic observed unique differences. The
progression of symptoms was notably slow, there was a
significant family history and unlike typical PD, there
were fewer nonmotor features. Prior to this report, there
were only few cases briefly mentioned in the literature.
The authors referred to this condition as benign
tremulous Parkinsonism (BTP). Since then a debate has
surfaced whether BTP represents a unique disorder or
the clinicians are facing a variant within the spectrum of
tremor-predominant idiopathic PD [10, 42].
According to the Mayo Clinic series [21] which was
also later reinforced by other groups [26, 41], BTP is
characterized by rest and action tremor at onset that re-
mains persistent as the dominant feature for at least 8
years with only a minimal progression of other parkin-
sonism signs. The gait disorder essentially comprises of
mild stooping or a reduced arm swing instead of classic
shuffling gait with progressive deterioration of balance.
These patients display a poor and unpredictable re-
sponse to levodopa therapy. Most of them present at a
relatively younger age of onset in the fifth decade and
have a family history which suggests a strong underlying
genetic etiology. The prognosis is much better compared
to idiopathic PD. Postmortem findings indicate fewer
pathological changes in the substantia nigra further con-
solidating the concept that BTP is a distinct entity [41].
Some argue BTP represents one end of the clinical
spectrum of PD which is tremor-predominant PD [10].
This subtype typically progresses the slowest amongst
the various PD subtypes and the presence of significant
motor findings in the beginning may be minimal. In an
editorial on study by Selikhova et al., it was recom-
mended that patients with rest and action tremors and
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minimal Parkinsonism features should be categorized as
“monosymptomatic tremor at rest”. Since only some of
the patients initially diagnosed as BTP eventually dis-
played typical pathological features of PD, it was felt that
BTP was a misnomer [10] (Table 1).
Whether BTP should truly be considered “benign” is
controversial. The term “benign” was proposed due to
a slower rate of progression of other Parkinsonism
symptoms which could indicate a better prognosis
than idiopathic PD. However, there is a suggestion
that these patients may also have sudden worsening of
other Parkinsonian signs, such as rigidity and gait
resulting in significant motor disability [39]. Another
example of “benign” movement disorder, is essential
tremor which was labeled as “benign” for decades in
literature until the most recent years, when gait dys-
function and memory problems in ET became well-
known. Considering these additional features, some
experts recommend avoiding the term “benign” when
describing ET. Similarly, clinicians must also be cau-
tious regarding the usage of the term “benign” in the
context of BTP until further longitudinal studies can
better establish or refute such an assumption. Follow-
up studies should focus on the rate of progression,
and the co-occurrence of non-motor symptoms.
Pathological findings in BTP
There is scant knowledge on the neuropathology of
BTP. In one study, Selikhova M. et al. compared brain
pathology specimens of 15 BTP cases with age and
disease duration-matched PD controls. They found
that most BTP patients had lesser neuronal loss in the
ventrolateral portion of the substantia nigra than their
PD controls. Similar to PD, BTP cases had Lewy bod-
ies in the substantia nigra and other brainstem struc-
tures. These findings suggest there is a slower nigral
cell degeneration which correlates with relatively
stable Parkinsonism observed throughout the clinical
course of BTP. It is noteworthy that tremor predomin-
ant subtype of PD also has lesser neuronal loss in
locus coeruleus (LC) and in medial and lateral parts of
substantia nigra [20]. Therefore, it will be worthwhile
to conduct a pathology study that could identify the
key differences between BTP and tremor predominant
PD.
Genetic aspects
A striking finding to note with BTP is the positive family
history of tremor identified in nearly 31 to 63 % of pa-
tients [21, 41], in contrast to only 7 to 16 % of idiopathic
PD patients [12, 32, 34, 35, 38]. These findings are in
contrast to a lower prevalence of family history in idio-
pathic PD (<10 %) and highlight an underlying genetic
etiology to play a substantial role.
The genetic underpinnings of BTP albeit intriguing,
only few cases have shown positive gene tests. LRRK2
mutation is responsible for about 1 % of sporadic PD pa-
tients and 4 % of hereditary PD cases. Clarimon J. et al.
in a series of patients who had clinical characteristics
similar to BTP, found new LRRK2 (V2390M) mutation.
Although authors allude to clinical similarities between
their patients and the BTP case series from Mayo, the
authors refer to the patients as tremor dominant parkin-
sonism [9]. Rizzo et al. [37] described another patient
with Dardarin mutation who had clinical presentation
consistent with BTP. In addition, compound heterozy-
gous parkin gene mutation was identified in one patient
[41]. Both LRRK2 mutations and parkin gene have been
linked to various heterogeneous phenotypes in idiopathic
PD [7, 16]. Considering the presence of significant family
history, further studies are required to identify the
underlying genetic aspect of BTP [29, 30].
Clinical features
As reported in multiple case series [21, 26, 41], the pre-
senting symptom in BTP is a moderate asymmetric
upper limb tremor [21], with majority presenting with a
combination of rest and postural/action tremors [41].
These tremors tend to only slowly worsen over time,
and typically do not respond to alcohol [21]. In the early
course of BTP, only mild features of Parkinsonism such
as bradykinesia, rigidity, stooped posture and a reduced
arm swing were observed [21, 41]. Interestingly, these
Parkinsonian signs remain relatively unchanged for
many years. Only few patients develop mild non-motor
symptoms including dysautonomia, constipation, erectile
Table 1 Clinical Characteristics of patients with Benign Tremulous Parkinsonism
Study Sex
(M/F)
Mean Age of onset
(range)
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dysfunction, and bladder dysfunction [21]. There is a
male predominance and the age of onset is relatively
younger ranging from 58.5 to 66.6 years [21, 26, 41].
Diagnosis
It is important to differentiate BTP from other similar
tremor syndromes [36], including the commonly seen
tremor-predominant PD and essential tremor. Each al-
ternative tremor syndromes has specific features which
should be given due consideration when making the
diagnosis.
1) Mono-symptomatic resting tremor, identified as a
pure or predominant rest tremor: These patients
however do not have other Parkinsonism symptoms
and signs [11].
2) Essential tremor: BTP tremors are postural +/−
kinetic and there is a strong family history. However
unlike the tremor of BTP, use of alcohol attenuates
tremors and there are no accompanying features of
parkinsonism [22].
3) Isolated tremor and subtle Parkinsonian signs relevant
to aging [25]: The parkinsonian features manifest at
an older age which is different from BTP in which the
mean age of onset is usually less than 60 years.
5) PD initially manifesting as essential tremor: These
patients [6, 15], are characterized by a postural tremor
or head tremor who develop parkinsonian symptoms
later in life. Their clinical features and disease course
are consistent with typical idiopathic PD.
6) Combined essential tremor with PD [24]: In this
syndrome the rate of progression for PD follows the
typical course unlike patients with BTP.
7) “Tremor-predominant PD”: This term encompasses
a specific phenotype of PD to distinguish patients
who have prominent tremors as the main clinical
presentation from those who have akinetic-rigid type
or those who can be categorized into postural
instability-gait disturbance phenotype. The term has
a broader connotation and does not necessarily
imply presence of other key features of BTP includ-
ing remarkable family history, and a slow course of
progression.
BTP is relatively new, therefore lacks clinical validity and
specific diagnostic criteria. In the early stages, it maybe dif-
ficult to clinically differentiate BTP from typical idiopathic
PD. If there is dopamine depletion in the brain, the patient
is likely to suffer from PD [28]. The clinicians should con-
sider BTP if the patients present with prominent rest
tremor in conjunction with postural and action tremors.
BTP becomes very likely if tremor remains the major sign/
symptom with mild and stable Parkinsonism despite several
years of follow-up. The other clinical clues include the
absence of a satisfactory response to levodopa therapy and
a positive family history. A Dopamine transporter Single-
photon emission computed tomography (DAT SPECT) test
which is sensitive and specific for diagnosis of degeneration
related parkinsonism has not been reported in BTP, may be
helpful for diagnosis. If BTP is distinct from tremor pre-
dominant PD, DAT SPECT is expected to be normal [36].
Treatment
BTP patients have usually shown refractoriness to levo-
dopa therapy, particularly in the early disease stages,
despite reaching average doses of 900 mg/day [21, 40].
Selikhova et al. [41] found that in a series of 12 patients,
six patients had a transient early response to high doses
of levodopa (400–1250 mg/day), and over half of the pa-
tients did not have a satisfactory response to dopamin-
ergic therapy [41]. Interestingly, substantial levodopa
complications including dyskinesias have not been de-
scribed in these patients. The effect of medications other
than levodopa, particularly the neuroprotective agents
[8, 31] and anti-tremor medications, on the course and
tremor symptoms in these patients require further
studies.
Over the past decade, a large body of evidence has estab-
lished the application of deep brain stimulation (DBS) sur-
gery in the management of medication refractory tremors
for PD [13, 14, 18, 23, 27] and essential tremor [17, 33]. A
review of 15 BTP patients who received DBS showed sig-
nificant improvement of symptoms [40]. Of these, 12 pa-
tients received ventral intermediate (VIM) nucleus of the
thalamus (8 patients with unilateral and 4 with bilateral
leads). The remaining three patients received bilateral sub-
thalamic nucleus (STN) stimulation. All of these patients
received a mean levodopa challenge dose of 900 mg/d
(300 mg 3 times daily), with about half of them showing an
initial but suboptimal response, whereas the other half had
no benefit with levodopa use. Overall there was a satisfac-
tory response to either VIM or STN stimulation, with seven
patients being tremor-free and six patients remaining with
minimal residual tremor at their last follow-up visit. Upon
reviewing these impressive benefits, it appears BTP patients
would be suitable for DBS at earlier stages of disease. VIM
could be an appropriate target as tremors are the predom-
inant feature and other Parkinsonian signs are mild. The
current available data, is not adequate to establish practice
parameters for DBS which could be accomplished through
future well-powered studies.
Conclusion
BTP is clinically characterized by asymmetric tremors at
onset, tremors present at rest, postural and action
tremors and they remain as the prominent clinical fea-
ture for many years. These tremors donot respond to al-
cohol. Tremors are accompanied by other mild features
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of parkinsonism which do not progress at typical rates.
Unlike typical PD, there family history is significant and
the nonmotor features are not that frequent. Autopsy
studies have found fewer pathological changes in the
substantia nigra. Whether BTP is a distinct clinical entity
or is a subtype of PD is currently debatable. Treatment
of BTP is challenging, response to levodopa is poor even
when tried at high doses. Athough small scale studies
have shown bilateral DBS of VIM and STN to exhibit
excellent outcomes, prospective studies with larger sam-
ple sizes, and randomized target selection, are required
to determine the long-term efficacy and durability [40].
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